Syndax Pharmaceuticals, a late-stage biotech developing a novel therapy for treatment-resistant breast cancer, refiled terms for its IPO on Thursday after postponing the deal in June. The Waltham, MA-based company still plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Syndax Pharmaceuticals would command a fully diluted market value of $179 million.
Syndax Pharmaceuticals, which was founded in 2005, plans to list on the NASDAQ under the symbol SNDX. Deutsche Bank and Jefferies & Co. are the joint bookrunners on the deal.
